- Stifel initiated coverage of Surrozen Inc SRZN with a Buy rating and $19 price target.
- The regenerative medicine biotech started trading recently on NASDAQ via SPAC deal with Consonance-HFW Acquisition Corp.
- The price target represents an upside of 75%.
- The Company has two proprietary technology platforms that and it seeks to either activate or amplify wingless/integrated signaling to engender clinical benefit, analyst Dae Gon Ha writes.
- With lead programs SZN-1326 in moderate-severe ulcerative colitis and SZN-043 in severe alcoholic hepatitis, the analyst thinks proof of concept may emerge from Phase 1b patient studies.
- Price Action: SRZN stock is up 49.0% at $10.79 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
